Illumina (NASDAQ:ILMN) Director Keith Meister Sells 98,833 Shares of Company Stock

Illumina, Inc. (NASDAQ:ILMN) Director Keith Meister sold 98,833 shares of the company’s stock in a transaction on Wednesday, November 11th. The shares were sold at an average price of $216.87, for a total value of $21,433,912.71. Following the sale, the director owned 208,826 shares of the company’s stock, valued at approximately $45,288,094.62. The trade was a 32.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Illumina Stock Down 1.6%

ILMN stock opened at $209.55 on Friday. The company has a market cap of $31.68 billion, a PE ratio of 40.56, a price-to-earnings-growth ratio of 2.89 and a beta of 1.46. The business has a 50-day simple moving average of $249.32 and a 200 day simple moving average of $179.36. Illumina, Inc. has a 52 week low of $112.65 and a 52 week high of $309.35. The company has a quick ratio of 2.05, a current ratio of 2.63 and a debt-to-equity ratio of 0.57.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, October 29th. The life sciences company reported $1.62 earnings per share for the quarter, topping the consensus estimate of $1.36 by $0.26. The business had revenue of $1.17 billion during the quarter, compared to analysts’ expectations of $1.15 billion. Illumina had a net margin of 19.72% and a return on equity of 28.38%. Illumina’s revenue was up 4.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.34 earnings per share. Sell-side analysts anticipate that Illumina, Inc. will post 5.43 EPS for the current fiscal year.

Institutional Trading of Illumina

Several large investors have recently bought and sold shares of the business. BlackRock Inc. bought a new position in Illumina in the second quarter valued at about $3,374,423,000. WCM Investment Management LLC lifted its holdings in shares of Illumina by 45.5% in the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after acquiring an additional 1,851,848 shares during the last quarter. Primecap Management Co. CA bought a new position in shares of Illumina in the second quarter worth about $617,981,000. Ninety One UK Ltd lifted its holdings in shares of Illumina by 37,920.0% in the third quarter. Ninety One UK Ltd now owns 1,359,974 shares of the life sciences company’s stock worth $372,198,000 after acquiring an additional 1,356,397 shares during the last quarter. Finally, Jupiter Topco LLC acquired a new stake in shares of Illumina in the 2nd quarter valued at approximately $358,652,000. 89.42% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Illumina

These are some of the ILMN stories that stood out recently:

• Positive Sentiment: Illumina reported third-quarter revenue of $1.129 billion and net income of $220 million, raised its 2026 revenue outlook to $4.64 billion–$4.66 billion, and highlighted strength in clinical sequencing consumables. How Investors May Respond To Illumina (ILMN) Earnings Beat
• Positive Sentiment: The company expanded its molecular residual disease research portfolio with an ultrasensitive duplex sequencing workflow for circulating tumor DNA and was selected to provide whole-genome sequencing services for Singapore’s SG-INSIGHT precision-medicine study. These developments support its push into clinical oncology and sequencing applications. Illumina (ILMN) Unveils Duplex Sequencing Workflow For MRD Research
• Neutral Sentiment: Illumina’s chief accounting officer sold 267 shares under a pre-arranged Rule 10b5-1 trading plan, a relatively small transaction that may be less informative about the executive’s view of the company. SEC filing

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Leerink Partners upped their price target on shares of Illumina from $220.00 to $300.00 and gave the stock an “outperform” rating in a report on Tuesday, September 29th. Royal Bank Of Canada lifted their price objective on shares of Illumina from $230.00 to $310.00 and gave the company an “outperform” rating in a research note on Monday, October 5th. Piper Sandler lifted their price objective on shares of Illumina from $225.00 to $305.00 and gave the company an “overweight” rating in a research note on Monday, September 28th. Citigroup boosted their price objective on shares of Illumina from $113.00 to $210.00 and gave the company a “sell” rating in a research report on Monday, November 2nd. Finally, Weiss Ratings upgraded Illumina from a “hold (c)” rating to a “buy (b-)” rating in a research note on Monday, November 2nd. Ten investment analysts have rated the stock with a Buy rating, six have given a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, Illumina currently has a consensus rating of “Hold” and a consensus price target of $244.24.

About Illumina

Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.